Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
deals
9
×
life sciences
merck
9
×
national blog main
new york blog main
raleigh-durham blog main
san diego blog main
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
national top stories
new york top stories
raleigh-durham top stories
san diego top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
pfizer
startups
alzheimer's disease
cancer
cancer immunotherapy
gene therapy
gilead sciences
abbvie
amgen
astrazeneca
bayer
What
bio
roundup
drug
pfizer’s
acquisitions
amid
biggest
bombast
buy
cancer
caught
ceo
companies
company
coronavirus
crispr
debate
develop
discussion
efforts
growing
meso’s
miss
moves
nash
news
pandemic
patients
presidential
promise
response
talk
treatment
tuesday’s
vaccine
viewers
adding
aims
albert
alliance
Language
unset
unknown
Current search:
merck
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More